Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by the End TB Strategy of the World Health Organization (WHO). There is thus a critical need for evidence-based policy recommendations on the...
This document provides a summary of the evidence and recommendations for the use of SL-LPA for the detection of mutations associated with resistance to fluoroquinolones and SLID in patients with RR-TB and/or MDR-TB. The objectives of this policy guidance are to assess and compare the diagnostic accuracy ...
Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico,
Antibióticos Antituberculosos/farmacología,
Técnicas de Sonda Molecular,
Pruebas de Sensibilidad Microbiana,
Fluoroquinolonas/uso terapéutico,
Farmacorresistencia Bacteriana/genética,
Genotipo,
Mutación,
Tuberculosis Resistente a Múltiples Medicamentos/genética,
Mycobacterium tuberculosis/efectos de los fármacos,
Mycobacterium tuberculosis/genética
Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...
The global priorities for tuberculosis (TB) care and control are to improve case-detection and to detect cases earlier, including cases of smear-negative disease which are often associated with coinfection with the human immunodeficiency virus (HIV) and young age, and to enhance the capacity to diagnose ...
Commercial liquid culture systems and molecular line-probe assays have been endorsed by the World Health Organization (WHO) as gold standards for rapid detection of multidrug-resistant (MDR) tuberculosis (TB); however, because of technical complexity, cost and the requirement for sophisticated laboratory...